Abstract

Rapid diagnosis of acute myocardial infarction (AMI) is crucial for optimal patient management. Accurate diagnosis and time of onset of an acute event can influence treatment plans, such as percutaneous coronary intervention (PCI). PCI is most beneficial within 3 hours of AMI onset. MicroRNAs (miRNAs) are promising biomarkers, with potential of early AMI diagnosis, since they are released before cell death and subsequent release of larger molecules [e.g., cardiac troponins (cTn)], and have greater sensitivity and stability in plasma versus cTn regardless of timing of AMI onset. However, miRNA-based AMI diagnosis can result in false positives due to miRNA content overlap between AMI and stable coronary artery disease (CAD). Accordingly, we explored the possibility of using a miRNA profile, rather than a single miRNA, to distinguish between CAD and AMI, as well as different stages following AMI onset. First …

Date

2024

Authors

Xiang Ren, Ruyu Zhou, George Ronan, S Gulberk Ozcebe, Jiaying Ji, Satyajyoti Senapati, Keith L March, Eileen Handberg, David Anderson, Carl J Pepine, Hsueh-Chia Chang, Fang Liu, Pinar Zorlutuna

Journal

Lab on a Chip

Volume

24

Issue

23

Pages

5203-5214

Publisher

Royal Society of Chemistry